Potent and selective inhibitor of the transforming growth factor-β
) type I receptor activin receptor-like kinase ALK5 (IC50
= 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-β
-induced proliferation of human osteosarcoma cells. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells. Inhibits TGF-β
-induced EMT, migration, invasion and VEGF secretion in several human cancer cell lines.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline
Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542.
Laping et al.
SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman et al.
SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells.
Matsuyama et al.
Cancer Res., 2003;63:7791
TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells.
Watabe et al.
J.Cell Biol., 2003;163:163
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
Halder et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 431542 include:
Showing Results 1 - 10 of 135